Integra LifeSciences (NASDAQ:IART) Price Target Lowered to $26.00 at Bank of America

Integra LifeSciences (NASDAQ:IART) had its price target trimmed by Bank of America from $42.00 to $26.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has an underperform rating on the life sciences company’s stock.

Several other equities analysts have also recently weighed in on IART. StockNews.com cut Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Truist Financial dropped their price objective on Integra LifeSciences from $46.00 to $41.00 and set a hold rating on the stock in a research note on Friday, March 1st. Wells Fargo & Company cut shares of Integra LifeSciences from an overweight rating to an equal weight rating and decreased their target price for the company from $45.00 to $25.00 in a research note on Tuesday. Oppenheimer lowered shares of Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday. Finally, Citigroup upgraded shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price objective on the stock in a research note on Wednesday, April 3rd. Three analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of Hold and a consensus target price of $36.80.

Integra LifeSciences Trading Up 8.4 %

NASDAQ IART opened at $25.08 on Tuesday. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a 52 week low of $22.36 and a 52 week high of $51.12. The stock’s 50 day moving average price is $32.95 and its two-hundred day moving average price is $38.24. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. The business had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 earnings per share. As a group, analysts anticipate that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC raised its stake in Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares in the last quarter. Hexagon Capital Partners LLC raised its position in shares of Integra LifeSciences by 123.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after buying an additional 370 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of Integra LifeSciences during the 3rd quarter worth approximately $47,000. Valley National Advisers Inc. acquired a new stake in shares of Integra LifeSciences during the 1st quarter worth approximately $63,000. Finally, Covestor Ltd increased its stake in Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 921 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.